Top 50 Biotech VC Funds & Investors in Ireland (October 2026)
For AI agents: Short investor table (Markdown), Detailed investor list (Markdown)
| Investor | Relevant Deals | Geography | Stage | Focus | Round Size |
|---|---|---|---|---|---|
|
Enterprise Ireland
VC Fund
|
47 | Ireland, United States, United Kingdom | Seed, Venture - Series Unknown, Grant | Software, Health Care, Information Technology | $26k–$8.3M |
|
SOSV
VC Fund
|
42 | United States, China, Canada | Seed, Convertible Note, Pre-Seed | Biotechnology, Health Care, Software | $50k–$5M |
|
Western Development Commission
VC Fund
|
14 | Ireland, United States | Seed, Venture - Series Unknown, Series A | Health Care, Medical Device, Biotechnology | $702k–$17M |
|
Kernel Capital
VC Fund
|
9 | Ireland, United Kingdom, France | Seed, Venture - Series Unknown | Software, Information Technology, Health Care | $549k–$12M |
|
Irrus Investments
VC Fund
|
8 | Ireland, Sweden, United States | Seed, Venture - Series Unknown, Series A | Health Care, Medical Device, Biotechnology | $713k–$24M |
|
Atlantic Bridge
VC Fund
|
7 | United States, Ireland, United Kingdom | Series A, Series B, Seed | Software, Artificial Intelligence, Information Technology | $1.1M–$62M |
|
Fountain Healthcare Partners
VC Fund
|
7 | Ireland, United States, France | Series A, Series B, Series C | Health Care, Biotechnology, Medical | $3.3M–$110M |
|
AIB Seed Capital Fund
VC Fund
|
6 | Ireland, United States, Jersey | Seed, Series A | Software, Health Care, Medical | $549k–$8.1M |
|
HBAN
VC Fund
|
6 | Ireland, United Kingdom, United States | Seed, Venture - Series Unknown | Health Care, Software, Medical Device | $375k–$7.3M |
|
Seroba Life Sciences
VC Fund
|
6 | Ireland, United States, United Kingdom | Series A, Series B | Health Care, Biotechnology, Medical | $4.6M–$105M |
|
Faber
VC Fund
|
5 | Portugal, Germany, United Kingdom | Seed, Pre-Seed, Series A | Software, Artificial Intelligence, SaaS | $121k–$25M |
|
European Investment Bank
VC Fund
|
5 | France, Germany, Italy | Debt Financing, Post-IPO Debt, Venture - Series Unknown | Energy, Biotechnology, Health Care | $8.7M–$587M |
|
Elkstone Capital Partners
VC Fund
|
5 | Ireland, United Kingdom, United States | Seed, Series A, Venture - Series Unknown | Software, Artificial Intelligence, Health Care | $797k–$18M |
|
HBAN Medtech Syndicate
VC Fund
|
4 | Ireland | Seed, Series B | Medical Device, Medical, Health Care | $1.3M–$11M |
|
Boole Investment Syndicate
VC Fund
|
4 | Ireland, Estonia, United States | Seed, Series A | Biotechnology, SaaS, Software | $623k–$2.2M |
|
Atlantic Bridge University Fund
VC Fund
|
4 | Ireland, United States | Seed, Series A, Series B | Health Care, Medical Device, Big Data | $859k–$80M |
|
Act Venture Capital
VC Fund
|
3 | Ireland, United States, United Kingdom | Seed, Series A | Software, Artificial Intelligence, Information Technology | $1M–$13M |
|
Furthr VC
VC Fund
|
3 | Ireland | Seed, Venture - Series Unknown | Software, Medical Device, Medical | $753k–$17M |
|
Google Ventures
VC Fund
|
3 | United States, United Kingdom, Israel | Series A, Series B, Seed | Software, Health Care, Biotechnology | $1.1M–$121M |
|
HealthCap
VC Fund
|
3 | United States, Sweden, France | Series B, Series A | Biotechnology, Health Care, Medical | $6M–$92M |
|
ARCH Venture Partners
VC Fund
|
3 | United States, China, United Kingdom | Series A, Series B, Series C | Biotechnology, Health Care, Therapeutics | $9.1M–$230M |
|
The Yield Lab Europe
VC Fund
|
3 | Ireland, France, United Kingdom | Seed, Series A, Venture - Series Unknown | AgTech, Agriculture, Biotechnology | $605k–$10M |
|
SciFounders
VC Fund
|
3 | United States, Ireland, United Kingdom | Seed, Pre-Seed, Series A | Health Care, Biotechnology, Medical | $400k–$21M |
|
Diagnostics Polymers
VC Fund
|
3 | Ireland | Convertible Note, Venture - Series Unknown | Medical, Big Data, Health Care | $1.2M–$1.9M |
|
Artis Ventures
VC Fund
|
2 | United States, United Kingdom, India | Series A, Series B, Seed | Health Care, Biotechnology, Software | $2.1M–$127M |
|
Gaingels
VC Fund
|
2 | United States, Canada, United Kingdom | Seed, Series A, Venture - Series Unknown | Software, Artificial Intelligence, Health Care | $72k–$35M |
|
Lynett Capital
VC Fund
|
2 | United States, Kenya, Nigeria | Seed, Series A, Pre-Seed | FinTech, SaaS, Software | $230k–$49M |
|
Gotzee Ltd
VC Fund
|
2 | Ireland | Venture - Series Unknown | Medical, Big Data, Health Care | $1.2M–$1.9M |
|
Novartis Venture Fund
VC Fund
|
2 | United States, Switzerland, United Kingdom | Series B, Series A, Series C | Biotechnology, Health Care, Therapeutics | $5.1M–$107M |
|
Pareto Holdings
VC Fund
|
2 | United States, United Kingdom, France | Seed, Pre-Seed, Series A | Software, Artificial Intelligence, FinTech | $125k–$35M |
|
Enterprise Equity
VC Fund
|
2 | Ireland, United States, United Kingdom | Seed, Series B | Software, Information Technology, Health Care | $549k–$7.5M |
|
Infinity Capital
VC Fund
|
2 | United States, Ireland, Canada | Series B, Series D, Series A | Software, E-Commerce, Semiconductor | $4M–$50M |
|
Ascentifi
VC Fund
|
2 | Ireland | Seed, Series A, Venture - Series Unknown | Health Care, Medical Device, Medical | $2.3M–$34M |
|
Lightstone Ventures
VC Fund
|
2 | United States, Ireland, India | Series A, Series B, Series C | Biotechnology, Health Care, Therapeutics | $18M–$105M |
|
DeepIE Ventures Management Co.
VC Fund
|
2 | Ireland, France, Switzerland | Seed, Series A | Manufacturing, AgTech, Software | $648k–$5.5M |
|
SVG Ventures
VC Fund
|
2 | United States, Canada, Ireland | Pre-Seed, Seed | AgTech, Agriculture, Farming | |
|
Foresite Capital
VC Fund
|
2 | United States, United Kingdom, China | Series B, Series C, Series A | Biotechnology, Health Care, Medical | $17M–$270M |
|
First Citizens Innovation Banking
VC Fund
|
2 | United States, Canada, United Kingdom | Debt Financing, Series B, Series A | Software, Health Care, Biotechnology | $2M–$105M |
|
LSP Dementia Fund
VC Fund
|
2 | Belgium, Ireland, United States | Series A, Series B, Post-IPO Equity | Biotechnology, Health Care, Life Science | $39M–$39M |
|
WxNW
VC Fund
|
1 | Ireland | Seed | Sales, Consumer, Marketing | |
|
Fulcrum Global Capital
VC Fund
|
1 | United States, Canada, India | Series A, Series B, Venture - Series Unknown | Biotechnology, Agriculture, Farming | $2M–$20M |
|
Sandbox Industries
VC Fund
|
1 | United States, India, France | Series A, Seed, Series B | Health Care, Biotechnology, Software | $210k–$21M |
|
Tekla Capital Management
VC Fund
|
1 | United States, Switzerland, France | Series B, Series C, Series A | Biotechnology, Health Care, Therapeutics | $6.3M–$156M |
|
Cedas Foundation
VC Fund
|
1 | Ireland, United States | Seed | Biotechnology, Organic, Biopharma | $1.4M–$1.8M |
|
Cambridge Innovation Capital
VC Fund
|
1 | United Kingdom, United States, Ireland | Series A, Series B, Seed | Biotechnology, Health Care, Medical | $2M–$73M |
|
Blue Wire Capital
VC Fund
|
1 | United Kingdom, United States, France | Seed, Pre-Seed, Series A | Software, SaaS, FinTech | $550k–$36M |
|
EarlyBirdCapital
VC Fund
|
1 | Ireland | Seed | Medical, Health Care, Biotechnology | |
|
Cultivian Sandbox Ventures
VC Fund
|
1 | United States, Canada, Germany | Series A, Series B, Series C | Biotechnology, Agriculture, Farming | $2M–$80M |
|
ETV Capital SA
VC Fund
|
1 | Ireland, United States, United Kingdom | TV, Auctions, Computer | ||
|
HBM-MedFocus
VC Fund
|
1 | United States, Ireland | Series A, Series B, Series C | Medical Device, Health Care, Therapeutics | $5M–$26M |
| Access all 289 VC funds in Ireland Biotech startups. | |||||
Access 48,091 investors
822 industries, 177 countries. Updated daily. Emails and phones included.
Browse database — It's Free!Investor list
Enterprise Ireland is the government agency responsible for the development and funding of the indigenous business sector. Their mission is to accelerate the development of companies to achieve strong positions in global markets resulting in increased national and regional prosperity. It was founded in 1998 and headquartered in Dublin, Ireland.
Show more...Investment focus
- Industry: Software, Health Care, Information Technology
- Stage:Seed, Venture - Series Unknown, Grant
- Geography: Ireland, United States, United Kingdom
Investor stats
- Total investments: 894
- Round size: Seed $394k–$3.2M; Grant $26k–$5.5M; Venture - Series Unknown $560k–$8.3M
- Lead/follow: 29% lead, 71% follow
- Last fund: May invest from a new fund soon — raised $1.2M in 2021
Portfolio highlights
- Foodcloud — We connect businesses that have surplus food with Charities and Community Groups that need it.
- Amethyst Care — Amethyst Care is a startup that creates an AI-powered voice assistant for those with mobility difficulties.
- Full Health Medical — Full Health Medical patient empowerment tools that improve prevention healthcare are part of the healthcare ecosystem. FHM provides reliable digital innovation, designed by healthcare professionals that are keen to help patients live a healthy life, in response to a national scarcity of healthcare providers, the development of chronic disease, anda lack of transparency at the patient level. People provide lifetime access to preventive care healthcare across screening, diagnostics, education, treatment, and a record of their journey driven technology provides lifetime access to preventative healthcare custom designed at every step screening, diagnostics, education, and action plans that motivate individuals to address risks before they develop health problems.
SOSV offers pre-seed capital and follow-on financial support to startups focusing on deep technology and scientific innovation. Founders utilize purpose-built laboratory facilities and engineering spaces to accelerate product development and testing. The firm facilitates connections between entrepreneurs and a network of investors through structured matchmaking events and technology summits.
Show more...Investment focus
- Industry: Biotechnology, Health Care, Software
- Stage:Seed, Convertible Note, Pre-Seed
- Geography: United States, China, Canada
Investor stats
- Total investments: 3729
- Round size: Seed $150k–$5M; Pre-Seed $50k–$1.6M; Convertible Note $50k–$3.6M
- Lead/follow: 37% lead, 63% follow
- Last fund: Likely still investing — raised $306M in 2023
Portfolio highlights
- Halla — Halla Intelligence is a digital solution that leverages over 100 billion shopper and product data points to recommend and promote what grocery items.
- Simply Good Jars — Simply Good Jars is a B-Corp company that delivers healthy meals in reusable + returnable packaging through use of smart refrigerated kiosks placed in offices, transit centers, universities and health-systems. Driven by purpose to change that way people think about consumption, SGJ introduces sustainable business practices into their everydayoperations with a zero-waste goal. For every jar returned back to the company for reuse, they will help feed someone in need and ensure that no packaging materials end up in landfills.
- Verdex Technologies — Verdex Technologies is an advanced materials platform technology that uses nanofibers to disrupt industries. Verdex doesn't just compete, it innovates and disrupts.
Supporting communities to grow, investing in businesses to scale and planning for the future of the western region.
Show more...Investment focus
- Industry: Health Care, Medical Device, Biotechnology
- Stage:Seed, Venture - Series Unknown, Series A
- Geography: Ireland, United States
Investor stats
- Total investments: 45
- Round size: Seed $702k–$3.9M; Series A $2.2M–$11M; Venture - Series Unknown $753k–$17M
- Lead/follow: 18% lead, 82% follow
Portfolio highlights
- Ovagen — Ovagen is a biotechnology company that has developed the process of producing germ free (GF) chicken eggs and GF birds in commercial quantities for use primarily in the pharmaceutical industry. Ovagen can also provide a Contract Research Service and has extensive expertise in SPF poultry & rodent housing & husbandry, in specific poultry& rodent research technologies to GMP standards and in avian transgenics.
- Peroptyx — Peroptyx is a platform that provides managed solutions for machine learning. At Peroptyx, they have assembled and pre-screened a qualified network of data evaluators across the globe. They strategically match ideal evaluators with each product to ensure authentic experiences through consistency and appropriate real-world contexts.
- Galway Biomedical — Galway Biomedical partners with global medical device companies to bring complex braided devices from early concept through to full-scale production.
Kernel Capital is the independent manager of The Bank of Ireland Kernel Capital Venture Funds, one of the largest and most active sources of equity finance on the island of Ireland. Kernel leverage their extensive network to enable their portfolio companies recruit the highest caliber people, to break into new international markets and to generate revenues of scale. It is the only investment firm with venture capital Funds dedicated to both jurisdictions on the Island. Kernel have raised over €210M from investors which including their strategic partner Bank of Ireland, Invest NI, Enterprise Ireland, Galway University Foundation, The University of Limerick Foundation, The New York State Common Retirement Fund and undisclosed Family Offices. Consistently delivering strong financial returns for their investors Kernel have led more than 20 substantial trade sales to NASDAQ, NYSE, and LSE listed corporations.
Show more...Investment focus
- Industry: Software, Information Technology, Health Care
- Stage:Seed, Venture - Series Unknown
- Geography: Ireland, United Kingdom, France
Investor stats
- Total investments: 96
- Round size: Seed $549k–$2M; Venture - Series Unknown $1.2M–$12M
- Lead/follow: 51% lead, 49% follow
- Last fund: May invest from a new fund soon — raised $40M in 2013
Portfolio highlights
- Cirdan — Cirdan provides highly reliable, innovative LIS & imaging solutions for the acceleration & enhancement of diagnosis, optimized for pathology & clinical lab.
- preico — Preico Network empowers Web2 and Web3 developers to create, own, and monetize crypto-native AI models on a decentralized platform
- Pretto — Pretto is the only truly transparent online real estate price comparator.Pretto accompanies you until the signing of your loan, free of charge and without commitment.
Irrus Investments is the leading Irish business angel network with international connections. Fueling Irish innovation in medical devices, software, hardware, digital healthcare and life sciences.
Show more...Investment focus
- Industry: Health Care, Medical Device, Biotechnology
- Stage:Seed, Venture - Series Unknown, Series A
- Geography: Ireland, Sweden, United States
Investor stats
- Total investments: 34
- Round size: Seed $713k–$4.7M; Series A $2.2M–$9.2M; Venture - Series Unknown $1.2M–$24M
- Lead/follow: 18% lead, 82% follow
Portfolio highlights
- Novus Diagnostics — Sepsis causing pathogen diagnostics under 15 minutes
- Deciphex — Deciphex - Transforming Digital Pathology - we are focussed on the development of applications for clinical and veterinary pathology that improve productivity
- Vertigenius — Vertigenius designs and deploys customized exercises using an easy-to-use clinician portal and even uses a Vertigenius head sensor to consult and manage patients with dizziness and imbalance.
Atlantic Bridge is a Growth Equity Firm with a Cross Border Value Add strategy. We invest in deep technology companies in Europe and the US. Our team is made up of successful entrepreneurs and senior technology industry executives and we invest in strong ambitious entrepreneurs and management teams that have the passion and drive to scale up and exploit major growth opportunities. We help our portfolio companies expand and grow internationally through our global platform with our team and offices in London, Dublin, Munich, Paris and Palo Alto. Atlantic Bridge brings together a unique team of technology entrepreneurs, experienced managers, finance professionals, and investment experts. The team contains a wealth of international business experience across Europe, the UK and the US. They have worked together in various capacities for the last 30 years, bringing a true partnership approach to their firm and their investments. Its investors include the founders, leading institutional investors, and private investors with a track record of investment in successful technology companies. Atlantic Bridge has developed a unique and differentiated strategy that focuses on specific technology themes and the implementation of the “Atlantic Bridge Model” for scaling companies internationally. The “Bridge Model” accelerates the scale-up of technology companies in Europe and the US. This approach is highly differentiated and has delivered strong performance results to date.
Show more...Investment focus
- Industry: Software, Artificial Intelligence, Information Technology
- Stage:Series A, Series B, Seed
- Geography: United States, Ireland, United Kingdom
Investor stats
- Total investments: 154
- Round size: Seed $1.1M–$7.5M; Series A $5M–$26M; Series B $10M–$62M
- Lead/follow: 41% lead, 59% follow
- Last fund: May invest from a new fund soon — raised $97M in 2021
Portfolio highlights
- GloNav — GloNav develops global positioning system and satellite navigation technologies and products for the wireless handset and mobile consumer electronics device markets. It offers global positioning system radio frequency integrated circuits and single chip assisted-global positioning systems, which are used for low dropout tracking and cellularhandset integration. The company was founded in 2006 and is based in Newport Beach, California. It has locations in the United States, the United Kingdom, Ireland, and Taiwan. As of January 2008, GloNav, Inc. operates as a subsidiary of NXP B.V.
- Mindgard — Mindgard is the leading provider of AI Red Teaming solutions.
- Neurobell — NeuroBell develop novel EEG medical devices for early detection and monitoring of neonatal seizures.
Fountain Healthcare Partners is an Irish based life science venture capital fund. Fountain is exclusively focused on the life science sector. Specific areas of interest to them are: specialty pharma, medical devices, biotechnology and diagnostics. They will deploy the majority of their capital in Europe with a strong focus on Ireland.
Show more...Investment focus
- Industry: Health Care, Biotechnology, Medical
- Stage:Series A, Series B, Series C
- Geography: Ireland, United States, France
Investor stats
- Total investments: 57
- Round size: Series A $6.3M–$35M; Series B $5.5M–$68M; Series C $3.3M–$110M
- Lead/follow: 42% lead, 58% follow
- Last fund: May invest from a new fund soon — raised $140M in 2019
Portfolio highlights
- Palyon Medical — Palyon Medical Corporation is a medical device company developing technologies for the treatment of chronic pain, spasticity and other neurological diseases.
- Neuromod Devices — Neuromod is the global medical device company that developed Lenire, the FDA Approved tinnitus treatment device.
- Vivasure Medical — Pioneering the Future of Large-Bore Vessel Closure for Arterial and Venous Access. The first and only 100% bio-absorbable, sutureless patch..
The AIB Seed Capital Fund was established in 2007 to provide venture capital for companies at the seed and early stages of development across a range of sectors throughout the Republic of Ireland. The Fund was established under the Enterprise Ireland Seed and Venture Capital Programme 2007-2012. The Fund has a total of €30m under management with AIB and Enterprise Ireland both committing €15m. It is managed by experienced managers with extensive expertise in making seed and early stage investments, adding value and facilitating business success. The Fund managers are empowered to make seed investments of up to approximately €500,000. Furthermore, the Fund has the capacity to make investments in later rounds to support the continued growth of investee companies. The Fund will be managed by Enterprise Equity Venture Capital and the Dublin Business Innovation Centre. This unique partnership brings together extensive regional and investment expertise. Enterprise Equity will evaluate and manage all investments outside the city and county of Dublin, as well as investments that require in excess of €250,000 from the fund within the city and county of Dublin. Dublin Business Innovation Centre (DBIC) will evaluate and manage all investments within the city and county of Dublin when the initial investment amount required from the Fund does not exceed €250,000.
Show more...Investment focus
- Industry: Software, Health Care, Medical
- Stage:Seed, Series A
- Geography: Ireland, United States, Jersey
Investor stats
- Total investments: 49
- Round size: Seed $549k–$3.6M; Series A $1.1M–$8.1M
- Lead/follow: 18% lead, 82% follow
Portfolio highlights
- NewsWhip — NewsWhip is the world's most comprehensive content discovery and analytics database. Their suite of products give customers the ability to predict which stories will be important today, and understand how to create successful content over the long term.NewsWhip serves over 500 of the world's leading publishers, brands and agencies,including: Reebok, the Washington Post, Conde Nast, Google, MasterCard, BuzzFeed, Time Inc., and more. NewsWhip Spike is their real-time, predictive content discovery dashboard — offering a one-stop view of what's important across both the web and 5 social networks. Spike is the only tool that discovers stories within 2 minutes of publishing, and predicts their spread across social.NewsWhip Analytics is a database of how audiences have engaged with stories across every social network over the long term. NewsWhip customers use Analytics to benchmark how they stack up against competitors and track engagement trends around events and seasons.
- Offr — Offr is the new way to buy and sell property, quickly and transparently.
- Metabolomic Diagnostics — Metabolomic Diagnostics is a deep-tech company specialized in the development of novel biomarker based diagnostic solutions for complex diseases. The company has developed an effective pipeline to firstly identify diagnostic biomarker panels and then translate these panels into clinical assays ready for application in the clinical laboratory.Thispipeline combines the biomarker multiplexing capabilities of Mass Spectrometry, a powerful analytical technology, with the company’s own informatics and statistics solutions to deliver diagnostic innovation. This is reflected in Metabolomic Diagnostics’ strong and versatile IP portfolio of technical innovations and biomarkers.Our VisionMetabolomic Diagnostics’ primary vision is to develop a portfolio of diagnostic solutions which can determine, early in a woman’s pregnancy,her risk of developing major complications much later in her pregnancy and thus enabling personalized care, adapted to each woman’s individual needs. Pregnancy complications like preeclampsia, gestational diabetes, preterm birth, and in-uterine growth restriction, all have the potential to severely impact on the well-being of mother and child.The company’s innovative diagnostic solutions will assist clinicians in re-imagining how these conditions are managed: our novel risk assessment tools are specifically developed in conjunction with prenatal care providers to ensure they make a difference that really matters. This in turn will enable clinicians to improve pregnancy outcomes globally.Our solutions will empower pregnant women: accurate pregnancy risk information will allow a pregnant woman, in partnership with her care provider, to determine what prenatal care is best for her pregnancy.
HBAN is dedicated to raising the profile of business angel investment as an asset class on the island of Ireland and to promote the creation of business angel syndicates.
Show more...Investment focus
- Industry: Health Care, Software, Medical Device
- Stage:Seed, Venture - Series Unknown
- Geography: Ireland, United Kingdom, United States
Investor stats
- Total investments: 74
- Round size: Seed $623k–$3.6M; Venture - Series Unknown $375k–$7.3M
- Lead/follow: 35% lead, 65% follow
- Last fund: May invest from a new fund soon — raised $11M in 2018
Portfolio highlights
- Movetru — Movetru a wearable device that aims to reduce injury and enhance rehabilitation.
- Glitch Ads — GlitchAds intends to democratize advertising by "leveraging" adverts and artificial intelligence.
- Change by Degrees — Change by Degrees is closed. While our purpose is to give every person on the planet sustainability as a superpower, policy changes at European level and
Seroba is a leading European life sciences venture capital firm focused on value creation through backing winning innovations in biotech and medtech.
Show more...Investment focus
- Industry: Health Care, Biotechnology, Medical
- Stage:Series A, Series B
- Geography: Ireland, United States, United Kingdom
Investor stats
- Total investments: 48
- Round size: Series A $5.4M–$33M; Series B $4.6M–$105M
- Lead/follow: 35% lead, 65% follow
- Last fund: May invest from a new fund soon — raised $108M in 2017
Portfolio highlights
- Coave Therapeutics — Coave Therapeutics is active in the field of gene therapies in rare ocular and CNS (Central Nervous System) diseases.
- Perfuze — Perfuze was founded in 2018 by Wayne Allen and Liam Mullins. Perfuze is located within Galway City in the West of Ireland. The founders have over 30 years combined medtech experience within start-up and large corporations.Perfuze is developing innovative medical technology to treat acute ischemic stroke.Perfuze is developing innovative cathetertechnology to treat acute ischemic stroke. Their technology is intended to provide superior clinical outcomes in shorter procedural times; resulting in safe, cost-effective therapy. Perfuze was founded in 2018 by Wayne Allen and Liam Mullins. The founders have over 30 years combined medtech experience within start-up and large corporations. Perfuze is currently located in the Business Innovation Centre on the campus of the National University of Ireland, Galway, and is in the process of relocating to the IDA Business Park in Dangan, Galway.
- Azafaros — Azafaros aims at developing therapeutic agents for the treatment of rare metabolic disorders such as lysosomal storage disorders through oral administration of azasugar compounds. These novel, very promising agents were discovered by Professor Hans Aerts at Leiden University and Amsterdam UMC and are exclusively licensed to Azafaros.
Access 48,091 investors
822 industries, 177 countries. Updated daily. Emails and phones included.
Browse database — It's Free!Faber is a Lisbon-based venture capital firm investing in outstanding entrepreneurs who innovate at the intersection of science and technology to drive digital transformation and climate action. The firm combines a specialist focus on deep tech early-stage startups with dedicated funds, investment teams and expert advisors to actively help founders build global companies powered by AI/Data, Web3 or Ocean/Climate technologies. Faber’s unique approach in Southern Europe is led by an entrepreneurial management partnership and backed by notable thesis-driven institutions and private investors. Investing since 2013, the firm has been an early investor in hard tech companies such as Unbabel, SWORD Health, Codacy, iLoF or YData.
Show more...Investment focus
- Industry: Software, Artificial Intelligence, SaaS
- Stage:Seed, Pre-Seed, Series A
- Geography: Portugal, Germany, United Kingdom
Investor stats
- Total investments: 100
- Round size: Seed $595k–$5.2M; Pre-Seed $121k–$3M; Series A $2.5M–$25M
- Lead/follow: 30% lead, 70% follow
- Last fund: Likely actively investing — fresh fund, raised $34M in 2024
Portfolio highlights
- Porelio — Porelio is an environmental technology that provides purification technologies for water and industrial chemicals.
- Helix Robotics — We are building the first commercial soft manipulator
- ATMOS Space Cargo — ATMOS Space Cargo develops and manufactures space capsules to return cargo from space, microgravity experiments, Commercial products to entire rocket stages.
European Investment Bank operates as the lending institution of the European Union, offering loans, guarantees, and technical expertise to governments, businesses, and financial institutions. The organization focuses on areas such as climate action, digital transformation, housing development, and security-related initiatives. Its activities include funding large-scale infrastructure, supporting technology development, and facilitating access to capital for emerging and established enterprises. The bank also delivers advisory support to structure projects, improve investment readiness, and align initiatives with policy objectives.
Show more...Investment focus
- Industry: Energy, Biotechnology, Health Care
- Stage:Debt Financing, Post-IPO Debt, Venture - Series Unknown
- Geography: France, Germany, Italy
Investor stats
- Total investments: 600
- Round size: Post-IPO Debt $16M–$587M; Debt Financing $16M–$370M; Venture - Series Unknown $8.7M–$110M
- Lead/follow: 83% lead, 17% follow
Portfolio highlights
- RougeTx — RougeTx is a Netherlands-based biotech developing first-in-class small-molecule therapies for vascular diseases caused by pericyte dysfunction. Its lead candidate, RTX-001, targets hereditary haemorrhagic telangiectasia (HHT), an inherited disorder involving fragile blood vessels and recurrent bleeding.
- MedinCell — Join Medincell on a journey to transform global health with innovative therapies.
- Santander Brasil — Banco Santander in Brazil, its largest division in Latin America and one of the world's most important, accounting for 50%.
Elkstone is an investment firm, focusing on entrepreneurs, senior executives, institutional LPs, the venture community, and the Irish diaspora. The objective of the organization is to boost the economic value and overall well-being of the island of Ireland by expanding a network, facilitating deserving investments, and delivering excellent investment performance.
Show more...Investment focus
- Industry: Software, Artificial Intelligence, Health Care
- Stage:Seed, Series A, Venture - Series Unknown
- Geography: Ireland, United Kingdom, United States
Investor stats
- Total investments: 98
- Round size: Seed $797k–$5.8M; Series A $5.5M–$18M; Venture - Series Unknown $1.1M–$7.8M
- Lead/follow: 47% lead, 53% follow
- Last fund: Likely still investing — raised $108M in 2023
Portfolio highlights
- Entity — Entity's purpose is shape the future of web gaming by leveraging emerging technologies and maximizing the browser's capabilities. Our next-generation gaming hub, scheduled to arrive in 2027, will be a global place for players to discover, connect, and play together.
- ZeroRisk.io — ZeroRisk.io's Merchant Management Platform delivers advanced compliance and cybersecurity solutions. Gain insights, mitigate risks, and drive revenue. Book a demo today.
- Full Health Medical — Full Health Medical patient empowerment tools that improve prevention healthcare are part of the healthcare ecosystem. FHM provides reliable digital innovation, designed by healthcare professionals that are keen to help patients live a healthy life, in response to a national scarcity of healthcare providers, the development of chronic disease, anda lack of transparency at the patient level. People provide lifetime access to preventive care healthcare across screening, diagnostics, education, treatment, and a record of their journey driven technology provides lifetime access to preventative healthcare custom designed at every step screening, diagnostics, education, and action plans that motivate individuals to address risks before they develop health problems.
HBAN Medtech Syndicate
Show more...Investment focus
- Industry: Medical Device, Medical, Health Care
- Stage:Seed, Series B
- Geography: Ireland
Investor stats
- Total investments: 13
- Round size: Seed $1.3M–$11M
- Lead/follow: 15% lead, 85% follow
Portfolio highlights
- FeelTect — FeelTect’s technology, Tight Alright, is a pressure sensing, connected-health device for measuring and monitoring sub-bandage pressure during compression therapy, primarily for the millions of people worldwide with venous leg ulcers (VLUs). Compression is a proven therapy for VLUs, however if it’s applied too loose, it’s ineffective, and if it’stoo tight, it’s dangerous.
- Neurobell — NeuroBell develop novel EEG medical devices for early detection and monitoring of neonatal seizures.
- SymPhysis Medical — SymPhysis Medical's goal is to develop innovative technologies that treat a range of chronic diseases, putting the patient experience at the forefront of our design solutions to improve quality of life.About SymPhysis MedicalSymPhysis Medical's emergent technology, releaze, is a drainage technology to treat a common complication oflate-stage cancers, malignant pleural effusion (MPE). MPE causes significant shortness of breath and chest pain in up to 15% of patients with cancer.
Boole Investment Syndicate invests in new technology start-up's with scalability.
Show more...Investment focus
- Industry: Biotechnology, SaaS, Software
- Stage:Seed, Series A
- Geography: Ireland, Estonia, United States
Investor stats
- Total investments: 10
- Round size: Seed $623k–$2.2M
- Lead/follow: 0% lead, 100% follow
Portfolio highlights
- Ovagen — Ovagen is a biotechnology company that has developed the process of producing germ free (GF) chicken eggs and GF birds in commercial quantities for use primarily in the pharmaceutical industry. Ovagen can also provide a Contract Research Service and has extensive expertise in SPF poultry & rodent housing & husbandry, in specific poultry& rodent research technologies to GMP standards and in avian transgenics.
- eID easy — One integration - access a worldwide network of QTSPs & CAs, for eSignatures, eID authentication & eSealing. Ensure full compliance with regulations.
- ArrayPatch — Revolutionising drug delivery with painless microneedle patch technology. Backed by prestigious funding and award-winning innovation.
We invest in entrepreneurs with the ambition to create world-class companies of scale.
Show more...Investment focus
- Industry: Health Care, Medical Device, Big Data
- Stage:Seed, Series A, Series B
- Geography: Ireland, United States
Investor stats
- Total investments: 33
- Round size: Seed $859k–$4.2M; Series A $3.4M–$34M; Series B $16M–$80M
- Lead/follow: 55% lead, 45% follow
Portfolio highlights
- CroíValve — CroíValve is a developed a safe, effective, easy to use, percutaneous solution for treating all patients with severe Tricuspid Regurgitation
- PlasmaBound — PlasmaBound provides a step-change technology, termed Controlled Plasma Ablation (CPA), which facilitates the structural adhesive joining of lightweight materials, namely carbon and glass fibre reinforced composites. CPA technology will accelerate the use of these lightweight composite materials into multi-material structural assemblies, byenabling reliable adhesive joining which is stronger than the composite structures themselves.
- ProVerum Medical — The ProVee stent from Proverum Medical uses 3-D geometry which mirrors and engages with the anatomy of the prostate. The system alleviates Lower Urinary Tract Symptoms (LUTS) by opening the prostatic urethra, applying radial force to the prostatic lobes.
Technology-focused, investing capital and expertise to fuel growth in the most promising ideas and companies. Raised c.€600m across multiple funds and invest from seed to growth. We look for companies with potentially cutting-edge, category-defining businesses in markets including application software, IT infrastructure, communications, Internet and mobile. We help founders create and scale businesses globally. We work as a small team with diverse strengths accessing a community of over 200 founders. The teams and companies we back scale their investor base as they scale their business execution and ambition. We work closely with them in this process. Over the past 25 years have built a broad network of US and European investors and founders that share our vision and approach. Act is based in Dublin, Ireland. Our most recent funds are supported by the European Investment Fund.
Show more...Investment focus
- Industry: Software, Artificial Intelligence, Information Technology
- Stage:Seed, Series A
- Geography: Ireland, United States, United Kingdom
Investor stats
- Total investments: 165
- Round size: Seed $1M–$5M; Series A $2.3M–$13M
- Lead/follow: 45% lead, 55% follow
- Last fund: Likely still investing — raised $146M in 2022
Portfolio highlights
- Ubotica — Ubotica delivers live maritime intelligence powered by Orbital AI, using satellites and sensors to predict risk, confirm threats and deliver actionable evidence.
- Entity — Entity's purpose is shape the future of web gaming by leveraging emerging technologies and maximizing the browser's capabilities. Our next-generation gaming hub, scheduled to arrive in 2027, will be a global place for players to discover, connect, and play together.
- Fresco — Fresco powers connected cooking experiences for appliance brands, enabling faster launches, lower R&D costs, and continuous innovation.
We are a relationship driven early stage VC investor. We invest in and form close partnerships with the founders we back.We make initial investments at Seed to Series A stage in highly ambitious, born global Irish software and medtech companies. We are hands-on and support teams across key strategic areas to accelerate growth.In addition toproviding institutional investment at an early stage, we reserve significant capital for following on in subsequent rounds. We go the journey with founders.
Show more...Investment focus
- Industry: Software, Medical Device, Medical
- Stage:Seed, Venture - Series Unknown
- Geography: Ireland
Investor stats
- Total investments: 31
- Round size: Seed $797k–$6.3M; Venture - Series Unknown $753k–$17M
- Lead/follow: 39% lead, 61% follow
- Last fund: May invest from a new fund soon — raised $36M in 2019
Portfolio highlights
- WrxFlo — Optimise your supply chain with WrxFlo digitalisation platform. Unlock data-driven insights, automate compliance, and drive supply chain sustainability.
- Trustap — Learn how we make buying & selling online safe & secure, every time. Create an account for free today!
- Neurobell — NeuroBell develop novel EEG medical devices for early detection and monitoring of neonatal seizures.
GV supports innovative founders moving the world forward.
Show more...Investment focus
- Industry: Software, Health Care, Biotechnology
- Stage:Series A, Series B, Seed
- Geography: United States, United Kingdom, Israel
Investor stats
- Total investments: 1519
- Round size: Seed $1.1M–$15M; Series A $6M–$100M; Series B $15M–$121M
- Lead/follow: 30% lead, 70% follow
- Last fund: May invest from a new fund soon — raised $100M in 2014
Portfolio highlights
- ngmoco — ngmoco ("Next Generation MObile COmpany") is creating and producing games for the iPhone. CEO Neil Young is a former executive from Electronic Arts, where he oversaw the development of several hit titles. Another EA vet and partner at Kleiner Perkins, Bing Gordon, sits on the board. Kleiner is an investor through its iFund.
- SolveAI —
- EveryONE Medicines — EveryONE Medicines develops nucleic acid therapeutics for pathogenic genetic mutation of patients.
HealthCap, a life science investor and company creator. Our motivation is to find innovative ideas and invest that could impact healthcare and society.
Show more...Investment focus
- Industry: Biotechnology, Health Care, Medical
- Stage:Series B, Series A
- Geography: United States, Sweden, France
Investor stats
- Total investments: 141
- Round size: Series A $6M–$73M; Series B $12M–$92M
- Lead/follow: 26% lead, 74% follow
- Last fund: Likely still investing — raised $179M in 2024
Portfolio highlights
- Neobiomics — Advancing neonatal care through evidence-based clinical nutrition.
- AMRA Medical — AMRA Medical is a digital health company transforming medical research and clinical care using rapid whole-body MRI technology.
- Ultragenyx Pharmaceutical — Ultragenyx is focused on developing first-ever approved treatments for rare and ultrarare diseases and moving the rare disease community forward.
Access 48,091 investors
822 industries, 177 countries. Updated daily. Emails and phones included.
Browse database — It's Free!ARCH Venture Partners provides seed / early stage venture capital for technology firms in information technology, life sciences, and physical sciences
Show more...Investment focus
- Industry: Biotechnology, Health Care, Therapeutics
- Stage:Series A, Series B, Series C
- Geography: United States, China, United Kingdom
Investor stats
- Total investments: 475
- Round size: Series A $9.1M–$213M; Series B $15M–$230M; Series C $15M–$167M
- Lead/follow: 32% lead, 68% follow
- Last fund: Likely still investing — raised $3B in 2024
Portfolio highlights
- Oratomic — Oratomic is a Pasadena-based quantum computing company building fault-tolerant quantum computers with neutral atoms.
- Synchron — The endovascular brain computer interface.
- Soufflé Therapeutics — Soufflé Therapeutics is a biotechnology company specializing in the development of nucleic acid medicines designed for precise delivery and targeting of disease-causing cells. The company's mission is to create potent, precise, and safe medicines that can be tailored for a broad range of diseases by leveraging breakthroughs in genetic medicineand drug delivery technology.
The Yield Lab Europe is a €55m early stage Agrifood and Ag Tech fund which comprises an accelerator and a larger follow-on fund, investing in high tech companies with the potential to significant disrupt and improve our current systems of global food production, and to improve the environmental sustainability of the industry. The main fund invests€1m each into 10-12 companies over several follow on rounds, with the strongest accelerator companies expected to progress to the main fund. The Yield Lab Europe is also part of a global network of Agrifood Tech funds, with global headquarters in St Louis USA, and sister funds in LATAM and Singapore.
Show more...Investment focus
- Industry: AgTech, Agriculture, Biotechnology
- Stage:Seed, Series A, Venture - Series Unknown
- Geography: Ireland, France, United Kingdom
Investor stats
- Total investments: 40
- Round size: Seed $605k–$2.9M; Series A $2.1M–$10M; Venture - Series Unknown $1.7M–$9.6M
- Lead/follow: 35% lead, 65% follow
- Last fund: May invest from a new fund soon — raised $67M in 2021
Portfolio highlights
- BBLeap — Spray technology | Excellent spraying - flawless and no compromises, Precision Spraying with variable rates at plant level.
- BiOceanOr — BiOceanOr harnessed the power of Marine Biology and AI to deliver bio-guided services that optimize fish welfare and fish growth, while supporting aquaculture sustainability standards
- Marama Labs — Marama Labs is a developer of a novel UV-Vis spectroscopy technology for scientific-analytical instrumentation. It assists customers in identifying and measuring turbid samples' characteristics by using light's spectral properties. It offers an ultra-violet and visible spectrophotometer for measuring absorption, extinction, and scatteringspectra of clear and turbid liquids to help customers keep their samples intact, reduce sample preparation steps, and improve measurement turnaround time.
We invest in highly technical startups from idea-stage up to Series A.
Show more...Investment focus
- Industry: Health Care, Biotechnology, Medical
- Stage:Seed, Pre-Seed, Series A
- Geography: United States, Ireland, United Kingdom
Investor stats
- Total investments: 14
- Round size: Seed $3.2M–$5M; Pre-Seed $400k–$400k; Series A $2.5M–$21M
- Lead/follow: 29% lead, 71% follow
- Last fund: Likely still investing — raised $2.5M in 2024
Portfolio highlights
- Olio Labs — Olio Labs utilizes AI for combo therapeutics, optimizing and minimizing side effects through automated discovery of protein interactions.
- Current Surgical — Surgery Reinvented - Current Surgical targets early-stage solid tumors in areas where traditional surgical techniques fail.
- Luminate — Luminate Medical is developing LILY, the world's first pain-free and portable solution to prevent hair loss caused by chemotherapy.
Investment Fund
Show more...Investment focus
- Industry: Medical, Big Data, Health Care
- Stage:Convertible Note, Venture - Series Unknown
- Geography: Ireland
Investor stats
- Total investments: 3
- Round size: Venture - Series Unknown $1.2M–$1.9M
- Lead/follow: 0% lead, 100% follow
Portfolio highlights
- Metabolomic Diagnostics — Metabolomic Diagnostics is a deep-tech company specialized in the development of novel biomarker based diagnostic solutions for complex diseases. The company has developed an effective pipeline to firstly identify diagnostic biomarker panels and then translate these panels into clinical assays ready for application in the clinical laboratory.Thispipeline combines the biomarker multiplexing capabilities of Mass Spectrometry, a powerful analytical technology, with the company’s own informatics and statistics solutions to deliver diagnostic innovation. This is reflected in Metabolomic Diagnostics’ strong and versatile IP portfolio of technical innovations and biomarkers.Our VisionMetabolomic Diagnostics’ primary vision is to develop a portfolio of diagnostic solutions which can determine, early in a woman’s pregnancy,her risk of developing major complications much later in her pregnancy and thus enabling personalized care, adapted to each woman’s individual needs. Pregnancy complications like preeclampsia, gestational diabetes, preterm birth, and in-uterine growth restriction, all have the potential to severely impact on the well-being of mother and child.The company’s innovative diagnostic solutions will assist clinicians in re-imagining how these conditions are managed: our novel risk assessment tools are specifically developed in conjunction with prenatal care providers to ensure they make a difference that really matters. This in turn will enable clinicians to improve pregnancy outcomes globally.Our solutions will empower pregnant women: accurate pregnancy risk information will allow a pregnant woman, in partnership with her care provider, to determine what prenatal care is best for her pregnancy.
Artis Ventures has spent over a decade backing bold teams who take the hard path, building market-defining companies to re-shape, re-invent, and re-make industries.
Show more...Investment focus
- Industry: Health Care, Biotechnology, Software
- Stage:Series A, Series B, Seed
- Geography: United States, United Kingdom, India
Investor stats
- Total investments: 152
- Round size: Seed $2.1M–$35M; Series A $5M–$57M; Series B $18M–$127M
- Lead/follow: 39% lead, 61% follow
- Last fund: Likely still investing — raised $141M in 2023
Portfolio highlights
- GenHealth.ai — GenHealth.ai provides healthcare solutions using generative AI trained on encoded medical events. Its product is a generative healthcare AI publicly available. It includes a foundation transformer model (new neural networks with excellent memory), an API, and user applications that can generate and predict future sequences of health events usinghistorical events. Together they can be used to build a large variety of customized applications.
- Ozlo Sleep — Ozlo Sleep is a science-driven sleep and audio technology company that supports and simplifies sleep rituals for clinical benefits, without the use of medication.
- Stateless Networks — Performance, Visibility. Simplicity...It's time for a beautiful network. Stateless is transforming network operations for software-centric networking. Tying together deep network understanding with state-of-the-art distributed systems, cloud, data science and gaming expertise, Stateless transforms network visibility, performance andresponse and helps accelerate the transition to modern network platforms, tying together physical and virtual layers. Focused on the enterprise data center, Stateless currently partners with the world’s leading network and infrastructure vendors (including VMware (VMW), Cisco Systems (CSCO), Cumulus Networks and others) to deliver solutions to some of the world’s largest private data center operators. We’re looking for software and networking engineers in Greater Seattle and the Bay Area with expertise in one or more of the following areas: Distributed Systems, Service Oriented Architecture, Complex Event processing, Functional Programming, Virtualization, Network design and deployment, Network programming, Network troubleshooting, configuration and performance tuning and SDN. Bonus points for experience working with cloud infrastructure (AWS, Azure, OpenStack) or low-level systems software (linux kernel, hypervisors, compilers/language runtimes), complex gaming systems or graphics and computational geometry. For more information visit http://www.statelessnetworks.com/ or follow Stateless on Twitter: @statelessntwrks.see
Gaingels is a venture investment syndicate in service of the LGBT+ community and its allies, investing in companies with LGBT+ founders and C-suite leaders at all stages of growth, as well as in more established companies resolved on building more inclusive teams, with a global portfolio of 130+ companies and $70M in deployed investment capital to date. The Gaingels network also actively supports its portfolio in identifying and recruiting diverse talent to their C-suite and board leadership teams and fosters a vibrant global community of industry leaders, investors, operators, and entrepreneurs who share a common goal for positive social change through business and successful investments.
Show more...Investment focus
- Industry: Software, Artificial Intelligence, Health Care
- Stage:Seed, Series A, Venture - Series Unknown
- Geography: United States, Canada, United Kingdom
Investor stats
- Total investments: 1354
- Round size: Seed $1M–$8.1M; Series A $5M–$35M; Venture - Series Unknown $72k–$13M
- Lead/follow: 1% lead, 99% follow
- Last fund: Likely actively investing — fresh fund, raised $140k in 2026
Portfolio highlights
- Allara — Allara is your all-in-one virtual care team for hormonal, metabolic & gynecological conditions such as PCOS and Endometriosis.
- North.cloud — Automate your enterprise-grade cloud finance with zero effort. Our AI reduces your cloud bill by 50% without any risk, contracts, or technical work.
- Uvi — Uvi provides infrastructure that serves as a context and reasoning layer for enterprise AI agents. The platform resolves internal corporate vocabulary, tracks dependencies, and reconstructs the decision-making intent scattered across disparate systems like Jira, GitHub, and Slack. By unifying data fragments into an integrated knowledge network, it enables AI tools to process query objectives accurately while enforcing existing user access permissions at the retrieval stage.
Early-stage venture firm backing founders with world-changing potential. Portfolio includes Hadrian, Flutterwave, Onebrief and Long Wall.
Show more...Investment focus
- Industry: FinTech, SaaS, Software
- Stage:Seed, Series A, Pre-Seed
- Geography: United States, Kenya, Nigeria
Investor stats
- Total investments: 30
- Round size: Seed $230k–$3.1M; Pre-Seed $500k–$2.7M; Series A $2.5M–$49M
- Lead/follow: 0% lead, 100% follow
- Last fund: May invest from a new fund soon — last raise in 2018
Portfolio highlights
- idler — Push the frontier of your model
- Juxta — Juxta delivers infrastructure-free positioning for people, assets, and robots. Track indoors, outdoors, and GPS-denied environments with the Universal Positioning System, Software SDK, and Asset Tags.
- Luminate — Luminate Medical is developing LILY, the world's first pain-free and portable solution to prevent hair loss caused by chemotherapy.
Holding Company
Show more...Investment focus
- Industry: Medical, Big Data, Health Care
- Stage:Venture - Series Unknown
- Geography: Ireland
Investor stats
- Total investments: 2
- Round size: Venture - Series Unknown $1.2M–$1.9M
- Lead/follow: 100% lead, 0% follow
Portfolio highlights
- Metabolomic Diagnostics — Metabolomic Diagnostics is a deep-tech company specialized in the development of novel biomarker based diagnostic solutions for complex diseases. The company has developed an effective pipeline to firstly identify diagnostic biomarker panels and then translate these panels into clinical assays ready for application in the clinical laboratory.Thispipeline combines the biomarker multiplexing capabilities of Mass Spectrometry, a powerful analytical technology, with the company’s own informatics and statistics solutions to deliver diagnostic innovation. This is reflected in Metabolomic Diagnostics’ strong and versatile IP portfolio of technical innovations and biomarkers.Our VisionMetabolomic Diagnostics’ primary vision is to develop a portfolio of diagnostic solutions which can determine, early in a woman’s pregnancy,her risk of developing major complications much later in her pregnancy and thus enabling personalized care, adapted to each woman’s individual needs. Pregnancy complications like preeclampsia, gestational diabetes, preterm birth, and in-uterine growth restriction, all have the potential to severely impact on the well-being of mother and child.The company’s innovative diagnostic solutions will assist clinicians in re-imagining how these conditions are managed: our novel risk assessment tools are specifically developed in conjunction with prenatal care providers to ensure they make a difference that really matters. This in turn will enable clinicians to improve pregnancy outcomes globally.Our solutions will empower pregnant women: accurate pregnancy risk information will allow a pregnant woman, in partnership with her care provider, to determine what prenatal care is best for her pregnancy.
Learn about the approach the Novartis Venture Fund takes to investing in innovative life science companies developing biotechnology and biopharmaceutical therapeutics that address unmet patient needs.
Show more...Investment focus
- Industry: Biotechnology, Health Care, Therapeutics
- Stage:Series B, Series A, Series C
- Geography: United States, Switzerland, United Kingdom
Investor stats
- Total investments: 237
- Round size: Series A $5.1M–$81M; Series B $11M–$107M; Series C $9M–$75M
- Lead/follow: 25% lead, 75% follow
- Last fund: May invest from a new fund soon — raised $200M in 2009
Portfolio highlights
- Kynexis — Kynexis is leading the way in precision medicine, focusing on the treatment of cognitive impairment associated with schizophrenia (CIAS). Explore our innovative approach and our dedication to improving the lives of millions globally.
- Visiogen — Visiogen, Inc. is an ophthalmic medical device company specializing in the development of new vision alternatives for patients with cataracts, with and without presbyopia. As part of this mission, Visiogen created the Synchrony dual optic accommodating *intraocular lens (IOL)* for use in the surgical treatment of these conditions.The device isdesigned to provide patients with near, intermediate and distance vision in a seamless continuum without the need for glasses or contact lenses. To eliminate lens handling during surgery, the Synchrony dual optic IOL is provided in a pre-loaded injector. This patented technology has been approved in Europe with a CE Mark designation and is currently undergoing clinical trials in the United States.
- Rein Therapeutics — Rein Therapeutics is advancing a novel pipeline of first-in-class medicines to address unmet medical needs in orphan pulmonary and fibrosis indications.
Building world-changing companies in sunny Miami
Show more...Investment focus
- Industry: Software, Artificial Intelligence, FinTech
- Stage:Seed, Pre-Seed, Series A
- Geography: United States, United Kingdom, France
Investor stats
- Total investments: 627
- Round size: Seed $880k–$7M; Pre-Seed $125k–$3.5M; Series A $5M–$35M
- Lead/follow: 2% lead, 98% follow
Access 48,091 investors
822 industries, 177 countries. Updated daily. Emails and phones included.
Browse database — It's Free!Enterprise Equity (or EEVC) has an excellent reputation for providing capital to early stage and expanding business throughout Ireland. With the advantage of having a strong regional presence in Cork, Galway and Dundalk – in addition to Dublin – they have been successfully investing in internationally focused Irish companies for over 25 years, making us the longest established venture capital firm in Ireland. Each of the general partners of the firm has successful commercial investing experience in their own right as well as investing on behalf of EEVC. Their success to date is achieved through investment of capital in well managed, genuinely innovative and growth orientated businesses across a wide range of sectors, focused across the software sector and high technology manufacturing, particularly in the medical device industry. With three funds under management, Enterprise Equity has invested in excess of €50m in over 80 companies throughout Ireland, with many of their founders/companies based in or significantly operating from North America and other locations. In addition, the Enterprise Equity managed AIB Seed Capital Fund is actively investing in founders/companies at the seed or early stage, and the Fund has an overall committed fund size of €53m. EEVC will invest €0.25m to €1.5m per business from this fund. They are regulated by the Central Bank of Ireland under the MiFID Regulations (Markets in Financial Instruments Directive of the European Community). Enterprise Equity’s offices are based in Dublin, Cork, Galway, and Dundalk.
Show more...Investment focus
- Industry: Software, Information Technology, Health Care
- Stage:Seed, Series B
- Geography: Ireland, United States, United Kingdom
Investor stats
- Total investments: 51
- Round size: Seed $549k–$2.5M; Series B $2.6M–$7.5M
- Lead/follow: 10% lead, 90% follow
Portfolio highlights
- Phorest — Join 8000+ spas, barbers, hair, beauty and nail salon owners using the #1 management, scheduling, POS and appointment booking system. Try Phorest now!
- SurgaColl — SurgaColl Technologies is a medical device company developing novel tissue regeneration products for the surgical treatment of diseases of the bone, cartilage and other human tissue. Based on technology developed at the Tissue Engineering Research Group (TERG) of the Royal College of Surgeons in Ireland (RCSI), headed by Professor Fergal O’Brien,the company aims to become a leader in the field of regenerative medical devices.
- Metabolomic Diagnostics — Metabolomic Diagnostics is a deep-tech company specialized in the development of novel biomarker based diagnostic solutions for complex diseases. The company has developed an effective pipeline to firstly identify diagnostic biomarker panels and then translate these panels into clinical assays ready for application in the clinical laboratory.Thispipeline combines the biomarker multiplexing capabilities of Mass Spectrometry, a powerful analytical technology, with the company’s own informatics and statistics solutions to deliver diagnostic innovation. This is reflected in Metabolomic Diagnostics’ strong and versatile IP portfolio of technical innovations and biomarkers.Our VisionMetabolomic Diagnostics’ primary vision is to develop a portfolio of diagnostic solutions which can determine, early in a woman’s pregnancy,her risk of developing major complications much later in her pregnancy and thus enabling personalized care, adapted to each woman’s individual needs. Pregnancy complications like preeclampsia, gestational diabetes, preterm birth, and in-uterine growth restriction, all have the potential to severely impact on the well-being of mother and child.The company’s innovative diagnostic solutions will assist clinicians in re-imagining how these conditions are managed: our novel risk assessment tools are specifically developed in conjunction with prenatal care providers to ensure they make a difference that really matters. This in turn will enable clinicians to improve pregnancy outcomes globally.Our solutions will empower pregnant women: accurate pregnancy risk information will allow a pregnant woman, in partnership with her care provider, to determine what prenatal care is best for her pregnancy.
Infinity Capital are hypothesis-driven investors - constantly calibrating ideas through a Silicon Valley/technology network that they've been building for over two decades. Their extensive technology and operating backgrounds, combined with over a dozen years each of successful startup investing, have been essential in buildingcredibility and a reputation that resonates with entrepreneurs.
Show more...Investment focus
- Industry: Software, E-Commerce, Semiconductor
- Stage:Series B, Series D, Series A
- Geography: United States, Ireland, Canada
Investor stats
- Total investments: 34
- Round size: Series A $5.4M–$24M; Series B $9M–$50M; Series D $4M–$17M
- Lead/follow: 9% lead, 91% follow
- Last fund: May invest from a new fund soon — raised $2.4M in 2015
Portfolio highlights
- AltraTech — Next Generation Molecular Detection Discover Altratech Next Generation Molecular Detection Discover Altratech At Altratech, our mission is to enable next generation molecular detection.
- BioSapien — BioSapien is a pre-clinical biotech company developing novel biodegradable implantable products that deliver active pharmaceutical ingredients (APIs) for oncology indications with reduced systemic side effects. The applications for this technology are currently under investigation for pancreatic cancer and lung cancer. The intended pipeline ofindications is expected to expand into other cancers such as colorectal, breast, and stomach cancers. BioSapien's 3D-printed MediChip delivers FDA-approved toxic high-dose systemic therapies in a localized slow-release biodegradable mesh which is able to target tissues while improving patients' quality of care and life.
- Core Starters — Core Starters services startups and investors through blockchain-based decentralized services to solve real problems.
Discover start-up investing made simple. Access VC-led rounds, build your portfolio, and unlock growth at Ascentifi
Show more...Investment focus
- Industry: Health Care, Medical Device, Medical
- Stage:Seed, Series A, Venture - Series Unknown
- Geography: Ireland
Investor stats
- Total investments: 9
- Round size: Seed $2.3M–$11M; Series A $9.2M–$34M; Venture - Series Unknown $3M–$3.5M
- Lead/follow: 0% lead, 100% follow
Portfolio highlights
- CroíValve — CroíValve is a developed a safe, effective, easy to use, percutaneous solution for treating all patients with severe Tricuspid Regurgitation
- Vertigenius — Vertigenius designs and deploys customized exercises using an easy-to-use clinician portal and even uses a Vertigenius head sensor to consult and manage patients with dizziness and imbalance.
- X-BOLT Orthapaedics — X-Bolt Trauma Solutions for osteoporotic bone fixation. FDA 510(k) approved. Clinical studies include the WHITE One (n=100) and WHITE Four (n=1,140) randomized control trials.
Lightstone Ventures is a global venture capital firm that invests in personalized medicines and targeted therapeutics. Lightstone Ventures was founded in 2012 by the General Partners and other key members of the life science teams of Advanced Technology Ventures (ATV) and Morgenthaler. The firm was formed to capture the upside of investing in breakthrough life science companies during a time of unique opportunity in space.
Show more...Investment focus
- Industry: Biotechnology, Health Care, Therapeutics
- Stage:Series A, Series B, Series C
- Geography: United States, Ireland, India
Investor stats
- Total investments: 88
- Round size: Series A $20M–$95M; Series B $18M–$100M; Series C $20M–$105M
- Lead/follow: 25% lead, 75% follow
- Last fund: May invest from a new fund soon — raised $375M in 2021
Portfolio highlights
- Cerevance — Cerevance is a biotechnology company that develops novel therapeutics for neurological diseases, including chronic neurodegenerative conditions such as Alzheimer's disease, Parkinson's disease, frontotemporal dementia, and amyotrophic lateral sclerosis. Using a large and growing repository of over 15,000 human brain tissue samples, thecompany generates an unprecedented level of expression and epigenetic data, enabling the company to identify the most promising targets for the next generation of treatments for CNS disorders.
- Psivant Therapeutics — PsiThera is advancing programs across multiple targets from the TNF superfamily and beyond, where no oral therapies currently exist.
- Crystalys Therapeutics — Crystalys Therapeutics is a clinical-stage biopharmaceutical company transforming the treatment of gout.
DeepIE Ventures Management Co. operates as a venture capital firm.
Show more...Investment focus
- Industry: Manufacturing, AgTech, Software
- Stage:Seed, Series A
- Geography: Ireland, France, Switzerland
Investor stats
- Total investments: 11
- Round size: Seed $648k–$5.5M
- Lead/follow: 9% lead, 91% follow
Portfolio highlights
- eID easy — One integration - access a worldwide network of QTSPs & CAs, for eSignatures, eID authentication & eSealing. Ensure full compliance with regulations.
- ArrayPatch — Revolutionising drug delivery with painless microneedle patch technology. Backed by prestigious funding and award-winning innovation.
- Marama Labs — Marama Labs is a developer of a novel UV-Vis spectroscopy technology for scientific-analytical instrumentation. It assists customers in identifying and measuring turbid samples' characteristics by using light's spectral properties. It offers an ultra-violet and visible spectrophotometer for measuring absorption, extinction, and scatteringspectra of clear and turbid liquids to help customers keep their samples intact, reduce sample preparation steps, and improve measurement turnaround time.
We work with leading corporations, startups, universities, and growers to solve the biggest challenges facing the agtech and foodtech industries.
Show more...Investment focus
- Industry: AgTech, Agriculture, Farming
- Stage:Pre-Seed, Seed
- Geography: United States, Canada, Ireland
Investor stats
- Total investments: 86
- Lead/follow: no public data
Portfolio highlights
- FarmWise — FarmWise provides technology-based services that allow farmers to streamline farm operations and increase food production efficiency.
- Napigen — We are the genome editing company specialized for mitochondrial engineering. We address unmet needs of future food supplies by creating hybrid crop plants to boost their yields to an unprecedented level. The company’s technology creates robust male sterile lines that are ideal over conventional lines because of their stability and elitebackgrounds. This allows the production of non-GM hybrid seeds in crop plants that are currently mostly non-hybrid such as wheat. Our technology solution is expected to fulfill the highest level of public acceptance and aspiration.
- Iamus Technologies — Iamus Technologies Limited is an Artificial Intelligence & Robotics company based in Ireland that has developed poultry specific robotic technology that empowers poultry farmers to make better and safer production decisions. Over the last 2 years we have been working globally with poultry processors in identifying KPIs that our robots cancontinuously gather on the ground in poultry sheds and feedback instantly to both producer and the relevant personnel back at the processing plant. Results to date are impressive with automatic and accurate data recovery from the birds on every part of the floor and analysis with real-time intervention now possible. These factors are key in addressing the growing demands of modern, intensive broiler production with the Iamus robot & platform meeting these requirements.
We are a multi-stage investment firm, investing in companies that leverage biology and big data to transform healthcare.
Show more...Investment focus
- Industry: Biotechnology, Health Care, Medical
- Stage:Series B, Series C, Series A
- Geography: United States, United Kingdom, China
Investor stats
- Total investments: 225
- Round size: Series A $17M–$165M; Series B $24M–$140M; Series C $37M–$270M
- Lead/follow: 28% lead, 72% follow
- Last fund: Likely still investing — raised $900M in 2024
Portfolio highlights
- Thyme Care — Thyme Care is a dedicated team of nurses and care experts offering value-based cancer care to help you through all phases of the cancer experience.
- Korsana Biosciences — Korsana Biosciences develops THETA-enabled antibody therapies for neurodegenerative diseases. The company focuses on shuttled monoclonal antibodies that cross the blood-brain barrier to reach central nervous system targets. Its lead program, KRSA-028, is an investigational anti-amyloid beta antibody for Alzheimer’s disease that uses a transferrinreceptor-based shuttle and Fc engineering to improve brain delivery and dosing. Korsana is also advancing additional THETA-based programs for undisclosed neurodegenerative indications.
- Khartis Therapeutics — Khartis is a drug discovery company developing oral therapies for patients with immune-mediated and chronic diseases. The company focuses on discovering and developing drug candidates intended to address chronic conditions and immune-mediated diseases.
First Citizens Innovation Banking works with technology, life science, cleantech, venture capital, private equity, and premium wine businesses. SVB provides industry knowledge and connections, financing, treasury management, corporate investment, and international banking services to its clients worldwide through 27 U.S. offices and seven international operations. Banking innovative companies and exclusive wineries, Silicon Valley Bank’s diverse financial services, knowledge, global network, and world-class service increase its clients’ probability of success. Forbes Magazine ranks SVB among America’s Best Banks, and Fortune Magazine named SVB one of the Best Companies to Work For in 2012.
Show more...Investment focus
- Industry: Software, Health Care, Biotechnology
- Stage:Debt Financing, Series B, Series A
- Geography: United States, Canada, United Kingdom
Investor stats
- Total investments: 791
- Round size: Series A $5.3M–$27M; Series B $8M–$45M; Debt Financing $2M–$105M
- Lead/follow: 41% lead, 59% follow
- Last fund: May invest from a new fund soon — last raise in 2016
Portfolio highlights
- Zogenix — Therapeutic Solutions for CNS Disorders and Rare Diseases
- Capitolis — Capitolis is the technology company helping to create safer and more vibrant financial markets by unlocking capital constraints and enabling greater access to more diversified capital and investment opportunities. Rooted in advanced technology and deep financial expertise, Capitolis powers groundbreaking financial solutions that drive growth forglobal and regional banks – and institutional investors alike.
- Torch Systems — Ultra early fire detection and analytics platform. Built for communities, enterprises, and the environment
Providing capital plus strategic, clinical, operational, financial, and commercial support to deliver the added value inventors seek.
Show more...Investment focus
- Industry: Biotechnology, Health Care, Life Science
- Stage:Series A, Series B, Post-IPO Equity
- Geography: Belgium, Ireland, United States
Investor stats
- Total investments: 5
- Round size: Series A $39M–$39M
- Lead/follow: 60% lead, 40% follow
Portfolio highlights
- Aerska — Aerska develops targeted RNA medicines to treat brain diseases. By silencing genes that cause harm, we can preserve the minds and memories of those we love.
- QurAlis — QurAlis is a operator of a biotechnology company intended to discover and develop potential precision therapeutics for amyotrophic lateral sclerosis (ALS). The company focuses on the link between genetics and disease in ALS and other neurological diseases, enabling doctors to successfully treat ALS .
- New Amsterdam Pharma — We're advancing a new era of treatment for cardiovascular disease and other lipid-related conditions.
WxNW operates as an investment firm.
Show more...Investment focus
- Industry: Sales, Consumer, Marketing
- Stage:Seed
- Geography: Ireland
Investor stats
- Total investments: 2
- Lead/follow: no public data
Portfolio highlights
- Ovagen — Ovagen is a biotechnology company that has developed the process of producing germ free (GF) chicken eggs and GF birds in commercial quantities for use primarily in the pharmaceutical industry. Ovagen can also provide a Contract Research Service and has extensive expertise in SPF poultry & rodent housing & husbandry, in specific poultry& rodent research technologies to GMP standards and in avian transgenics.
- UrbanFox — Discover cutting-edge AI data processing solutions tailored to your needs. Elevate your business with innovative technology, personalized service, and a commitment to excellence.
Access 48,091 investors
822 industries, 177 countries. Updated daily. Emails and phones included.
Browse database — It's Free!Feeding the world one investment at a time
Show more...Investment focus
- Industry: Biotechnology, Agriculture, Farming
- Stage:Series A, Series B, Venture - Series Unknown
- Geography: United States, Canada, India
Investor stats
- Total investments: 25
- Round size: Series A $3.8M–$13M; Series B $5.8M–$20M; Venture - Series Unknown $2M–$5M
- Lead/follow: 44% lead, 56% follow
- Last fund: Likely still investing — raised $79M in 2021
Portfolio highlights
- Sabanto — Sabanto brings autonomy to agriculture with retrofit kits that transform existing tractors into fully autonomous machines. Boost efficiency, reduce labor, and farm 24/7 with the Sabanto Autonomy System. Book a demo today.
- Plastomics — Plastomics is a biotechnology startup that focuses in developing the next generation of crops by using chloroplast genetic engineering. Its technology platform is applicable to different crops and traits. Plastomics provides solutions for the many current industry challenges.The company was founded in 2016 and headquartered in St. Louis,Missouri.
- TastyUrban — TastyUrban is in the process of developing a new generation of restaurant usage and strategy.
We invest in innovation to drive lasting change in human livelinhood. We foster innovation to drive lasting change in industries that are crucial to our industry: healthcare, insurance and sustainability.
Show more...Investment focus
- Industry: Health Care, Biotechnology, Software
- Stage:Series A, Seed, Series B
- Geography: United States, India, France
Investor stats
- Total investments: 107
- Round size: Seed $210k–$3.2M; Series A $1.7M–$16M; Series B $5.5M–$21M
- Lead/follow: 16% lead, 84% follow
- Last fund: Likely still investing — raised $72M in 2023
Portfolio highlights
- Anzen — Anzen is a management insurance and operations tool using real-time HRIS and SaaS integrations to identify and avoid management risks. The company was founded in 2020 and is headquartered in San Francisco, California, United States.
- Big Health — Our mission is to help millions back to good mental health. Our digital therapeutics are safe and effective non-drug alternatives for mental health.
- Noctrix Health — Noctrix Health is an early-stage medical device company that focuses on developing a revolutionary therapy for a chronic illness.
We are dedicated to helping investors reach their investment goals. Get in touch with our team to explore Aberdeen's investment options.
Show more...Investment focus
- Industry: Biotechnology, Health Care, Therapeutics
- Stage:Series B, Series C, Series A
- Geography: United States, Switzerland, France
Investor stats
- Total investments: 53
- Round size: Series A $6.3M–$65M; Series B $20M–$156M; Series C $28M–$133M
- Lead/follow: 11% lead, 89% follow
Portfolio highlights
- Oculis — Experience the Future of Eye Care: Oculis, a Clinical Biopharmaceutical Innovator, Pioneering Breakthrough Treatments for Ophthalmic Diseases & Transforming Lives Globally.
- Amolyt Pharma — AstraZeneca is a global, science-led biopharmaceutical business and our innovative medicines are used by millions of patients worldwide.
- Endeavor BioMedicines — Endeavor BioMedicines is a clinical-stage biotechnology company developing transformational medicines for life-threatening diseases.
Cedas Foundation
Show more...Investment focus
- Industry: Biotechnology, Organic, Biopharma
- Stage:Seed
- Geography: Ireland, United States
Investor stats
- Total investments: 2
- Round size: Seed $1.4M–$1.8M
- Lead/follow: 50% lead, 50% follow
Portfolio highlights
- Hexafly — Hexafly is a biotechnology company that develops materials and sources form insects for aquafeed, chitin, and plant nutrition industry. It offers products from the sustainable farming of insects such as insect oil, protein, frass, and chitin. The company was founded in 2016 and headquartered in Kells, Meath, Ireland.
- BioSapien — BioSapien is a pre-clinical biotech company developing novel biodegradable implantable products that deliver active pharmaceutical ingredients (APIs) for oncology indications with reduced systemic side effects. The applications for this technology are currently under investigation for pancreatic cancer and lung cancer. The intended pipeline ofindications is expected to expand into other cancers such as colorectal, breast, and stomach cancers. BioSapien's 3D-printed MediChip delivers FDA-approved toxic high-dose systemic therapies in a localized slow-release biodegradable mesh which is able to target tissues while improving patients' quality of care and life.
As a team, we have a passion for science and its potential to drive change. Through our expertise and our position in one of the country's most powerful science and technology ecosystems, we're able to identify and support the most promising entrepreneurs in knowledge intensive businesses and help them achieve their vision.With our financial backing and expert guidance, we're excited to enable the pioneers in life sciences and deep tech to create world-leading companies whose unique ideas bring financial success and global impact.
Show more...Investment focus
- Industry: Biotechnology, Health Care, Medical
- Stage:Series A, Series B, Seed
- Geography: United Kingdom, United States, Ireland
Investor stats
- Total investments: 119
- Round size: Seed $2M–$31M; Series A $2.6M–$73M; Series B $8.2M–$68M
- Lead/follow: 37% lead, 63% follow
- Last fund: Likely actively investing — fresh fund, raised $332M in 2025
Portfolio highlights
- Trent AI — The agentic AI security platform that works like an AI security engineer, finding the real risk in your code, cloud, and AI agents and verifying every fix.
- Salience Labs — Salience Labs is building a hybrid photonic-electronic chip for AI. We have designed a massively parallel, ultra-high-throughput Photonic Tensor Processing Unit. Photonics allows data to be modulated at up to 100 GHZ, and allows for high levels of parallelization using multiplexing. We integrate this photonic unit into a SoC architecture designedto exploit its high throughput for AI inference. Salience Labs technology is based on decades of research collaboration between Oxford University and the University of Münster, Germany.
- TRIMTECH Therapeutics — Transformative treatments for CNS and inflammatory disorders by selectively destroying disease-causing protein aggregates
Investing globally in Frontier & Consumer businesses at pre-seed or seed.
Show more...Investment focus
- Industry: Software, SaaS, FinTech
- Stage:Seed, Pre-Seed, Series A
- Geography: United Kingdom, United States, France
Investor stats
- Total investments: 48
- Round size: Seed $866k–$6M; Pre-Seed $550k–$3.5M; Series A $7M–$36M
- Lead/follow: 19% lead, 81% follow
Portfolio highlights
- Ovo Labs — Ovo Labs is developing therapeutics that boost egg quality to enhance IVF success, technology aims to extend the timeline when the chances of conception are high.
- Ignota Labs — Ignota Labs for in silico toxicity prediction.
- Caribou — Transfer pricing software with the experts built in. We design it, document it, and keep it watertight as you grow.
EarlyBirdCapital, Inc. (“EBC”) is a registered broker-dealer1 and member of the Financial Industry Regulatory Authority, Nasdaq Stock Market, Inc., Municipal Securities Rule Making Board, and Securities Insurance Protection Corporation2. EBC is a boutique investment bank that has developed an expertise in working with smaller capitalizationcompanies, special situation investments and Special Purpose Acquisition Companies (SPACs:tm:), a new concept they pioneered and developed that involves publicly-traded, industry-specific acquisition funds.
Show more...Investment focus
- Industry: Medical, Health Care, Biotechnology
- Stage:Seed
- Geography: Ireland
Investor stats
- Total investments: 1
- Lead/follow: 100% lead, 0% follow
Portfolio highlights
- Perfuze — Perfuze was founded in 2018 by Wayne Allen and Liam Mullins. Perfuze is located within Galway City in the West of Ireland. The founders have over 30 years combined medtech experience within start-up and large corporations.Perfuze is developing innovative medical technology to treat acute ischemic stroke.Perfuze is developing innovative cathetertechnology to treat acute ischemic stroke. Their technology is intended to provide superior clinical outcomes in shorter procedural times; resulting in safe, cost-effective therapy. Perfuze was founded in 2018 by Wayne Allen and Liam Mullins. The founders have over 30 years combined medtech experience within start-up and large corporations. Perfuze is currently located in the Business Innovation Centre on the campus of the National University of Ireland, Galway, and is in the process of relocating to the IDA Business Park in Dangan, Galway.
Cultivian Sandbox is a venture capital firm focused on building next-generation disruptive agriculture and food technology companies capable of generating superior returns. As early investors and active board members, we employ a hands-on approach to building companies and are often directly involved in setting company strategy, recruiting key executives, and raising additional capital. Much more than simply a financial resource, we are capable of delivering tremendous value though active collaboration with our strategic partners and network, which are unparalleled in the agriculture and food industries. As both experienced operating managers and venture investors we add value to portfolio companies both through our highly skilled team and extensive industry network. Our investment team combines the domain expertise and investment experience from Cultivian Ventures and Sandbox Industries. Our expertise in sourcing, evaluating, closing, managing and ultimately exiting successful equity investments positions us not only to build stronger businesses, but reshape industries.
Show more...Investment focus
- Industry: Biotechnology, Agriculture, Farming
- Stage:Series A, Series B, Series C
- Geography: United States, Canada, Germany
Investor stats
- Total investments: 48
- Round size: Series A $2M–$23M; Series B $14M–$80M; Series C $13M–$22M
- Lead/follow: 50% lead, 50% follow
- Last fund: May invest from a new fund soon — raised $135M in 2019
Portfolio highlights
- Debut — Debut Biotech develops biotechnology-based beauty ingredients and formulations in a vertically integrated manner, beginning with AI-powered discovery and continuing through biosynthesis, biomanufacturing, downstream processing, and finished formulations. The company utilizes its BeautyORB platform to computationally screen vast chemical librariesand predict novel bioactives, which then proceed through validation, safety testing, and formulation for skincare and haircare applications. Debut employs both engineered microbial fermentation and cell-free enzymatic systems to produce these novel ingredients sustainably and then transitions them into proprietary formulations or custom white-label products.
- Culture Biosciences — Culture Biosciences provides a platform of cloud-connected bioreactors, software tools, and process development services that support upstream bioprocess development for biotech and biopharma applications. The company’s offerings include remote experiment design, monitoring, and data analysis through an integrated cloud software interface pairedwith single-use bioreactors for microbial fermentation and cell culture experimentation. Its services encompass clone and strain screening, process optimization, characterization, and bioprocess modeling to help scientific teams refine and scale their workflows. Clients access real-time data and analytics to inform decisions and collaborate across teams using the platform’s tools. Culture Biosciences’s technology is used to advance development of therapeutics, synthetic biology products, and related bioprocesses. Culture Biosciences was founded in 2016 and is headquartered in San Francisco, California.
- AbCelex Technologies — SpaceAble is building an on orbit inspector to contribute to a New Space resilience infrastructure based on certified data.
ETV is one of Europe's leading providers of debt financing solutions for venture capital backed technology and healthcare businesses. Founded in 1999, ETV has a long and successful track record of investing in technology or intellectual property based companies across Europe and Israel, diversified by industry and development stage. Theyseek to set their selves apart from other venture lenders by being supportive, flexible and responsive to the needs of their customers, and a testament to their approach is the number of serial entrepreneurs, business angels and senior management that have come back to ETV both through the lifecycle of a company’s growth and for their subsequent ventures.
Show more...Investment focus
- Industry: TV, Auctions, Computer
- Geography: Ireland, United States, United Kingdom
Investor stats
- Total investments: 3
- Lead/follow: 0% lead, 100% follow
Portfolio highlights
- 123.TV — German television channel, 123TV organizes cross-media auctions (TV and internet) on consumer products, for a public of all generations. The auction is reversed in the sense that the price fixed in advance to steady decreases over time until the amounts passed.
- Nallatech — BittWare provides enterprise-class FPGA hardware and integrated systems featuring technology from AMD, Altera, and Achronix. Accelerate your network, storage, and compute solutions with low-risk, production-ready acceleration cards.
- Stokes Bio — Stokes Bio develops and distributes microfluidic technology to its clients. It was founded in 2005 and is based in Ireland. It was acquired by Life Technologies in 2010.
MedFocus is a Private Equity Firm Dedicated to the Discovery and Investment in Emerging Medical Device Technology.
Show more...Investment focus
- Industry: Medical Device, Health Care, Therapeutics
- Stage:Series A, Series B, Series C
- Geography: United States, Ireland
Investor stats
- Total investments: 5
- Round size: Series A $5M–$26M; Series B $17M–$18M
- Lead/follow: 60% lead, 40% follow
Portfolio highlights
- Perfuze — Perfuze was founded in 2018 by Wayne Allen and Liam Mullins. Perfuze is located within Galway City in the West of Ireland. The founders have over 30 years combined medtech experience within start-up and large corporations.Perfuze is developing innovative medical technology to treat acute ischemic stroke.Perfuze is developing innovative cathetertechnology to treat acute ischemic stroke. Their technology is intended to provide superior clinical outcomes in shorter procedural times; resulting in safe, cost-effective therapy. Perfuze was founded in 2018 by Wayne Allen and Liam Mullins. The founders have over 30 years combined medtech experience within start-up and large corporations. Perfuze is currently located in the Business Innovation Centre on the campus of the National University of Ireland, Galway, and is in the process of relocating to the IDA Business Park in Dangan, Galway.
- Shape Memory Medical — Smart polymer. Smart embolization. Smart choice. Reshaping your view of clinical success through the science of smart polymer.
- Viseon — Experience Viseon's Advanced Digital Visualization CRANIALSPINALExperience Viseon's
Biotech VC funding in Ireland at a glance
Stats across 326 deals from 289 investors.
Access all 289 VC funds in Ireland Biotech startups.
Open ListFAQ
Is Shizune data fresh/accurate?
Shizune has monitored hundreds of funding sources since 2020.
Our investor database is updated every day, so investor data is always fresh.
All metrics are calculated from confirmed public rounds, so the data is accurate.
Can I download investor list?
To download the Biotech VC Funds in Ireland investor list, create a Shizune account. This investor list will be added to your saved investors and available for download in the export section.
You can also enrich the investor list with investor emails, phones, LinkedIns, and other contact data.
Can I access investor database?
To access all 289 VC funds investing in Ireland Biotech startups and 48,091+ more investors, create a Shizune account.
Shizune has a database of 48,091 investors. Our investor database is fresh and updated daily.
The Shizune investor database has information on investor investment focus, investor contact data, and full investor portfolio since 2020.
You can enrich with email and download the data.
Does Shizune have investor emails and contacts?
Shizune enriches investors with contact data that includes: email, phones, LinkedIn, socials, website, and others.
To guarantee the highest discovery rate, we search across 20+ contact search tools.
To maximize delivery rate and reduce bounce rate, we validate emails.
You can enrich your investor list with Shizune. Download it too.
What is Shizune?
Shizune is a 48,091 investor database updated daily.
With Shizune you can:
- browse the database
- use smart matching
- enrich with emails
- download
All you need to find investors for your startup.
Who is Shizune for?
Shizune is built for startup founders by startup founders.
If you are looking for funding for your startup, try the Shizune database — we have investors for every stage, industry, and country.
Is Shizune free?
Shizune is free forever. You can search and browse investors for free.
Email search and export are paid features.
For full info, visit our pricing.
Who built Shizune?
Shizune is built by founders with the goal of helping all founders raise funding no matter where they are.
Contact 100 investors today
Find who invests in your industry, stage, and country. Download investor list with emails in 5 minutes.
Find investors — It's Free!